Channel Therapeutics (PTHS) Income Statement (2023 - 2026)
Income Statement report data from Mar 31, 2023 to Mar 31, 2026 for Channel Therapeutics (PTHS).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | |||||||||||||
Total Revenue | 11M (-33.88%) | 17M (+5589.66%) | 290K | - | - | - | - | - | - | - | - | - | - |
Operating Expenses | |||||||||||||
Research And Development | 190K (-48.65%) | 370K (+164.29%) | 140K (-72.55%) | 510K (+168.42%) | 190K (-32.14%) | 280K (-33.33%) | 420K (+4100.00%) | 10K (-97.87%) | 470K (-79.48%) | 2.29M (+4480.00%) | 50K (0.00%) | 50K (-73.68%) | 190K |
Selling General And Administrative | 21M (+5.13%) | 20M (+2.24%) | 20M (+1668.47%) | 1.11M (-32.32%) | 1.64M (-40.58%) | 2.76M (+69.33%) | 1.63M (+34.71%) | 1.21M (+53.16%) | 790K (-25.47%) | 1.06M (+60.61%) | 660K (+22.22%) | 540K (+12.50%) | 480K |
Operating Expenses | 24M (+12.16%) | 21M (-6.06%) | 23M (+604.95%) | 3.23M (+76.50%) | 1.83M (+0.55%) | 1.82M (-11.22%) | 2.05M (+16.48%) | 1.76M (-8.81%) | 1.93M (-50.26%) | 3.88M (+200.78%) | 1.29M (+65.38%) | 780K (-14.29%) | 910K |
Depreciation And Amortization | 470K (-35.62%) | 730K | - | - | - | - | - | - | - | - | - | - | - |
Operating Income | |||||||||||||
Operating Income | -13.09M (+9.08%) | -12.00M (-21.88%) | -15.36M (+375.54%) | -3.23M (+76.50%) | -1.83M (+0.55%) | -1.82M (-11.22%) | -2.05M (+16.48%) | -1.76M (-8.81%) | -1.93M (-50.26%) | -3.88M (+200.78%) | -1.29M (+65.38%) | -780.00K (-14.29%) | -910.00K |
Ebit | -13.09M (+9.08%) | -12.00M (-21.88%) | -15.36M (+375.54%) | -3.23M (+76.50%) | -1.83M (+0.55%) | -1.82M (-11.22%) | -2.05M (+16.48%) | -1.76M (-8.81%) | -1.93M (-50.26%) | -3.88M (+200.78%) | -1.29M (+65.38%) | -780.00K (-14.29%) | -910.00K |
EBITDA | -12.62M (+14.10%) | -11.06M (-27.99%) | -15.36M (+345.22%) | -3.45M (+88.52%) | -1.83M (+15.82%) | -1.58M (-4.82%) | -1.66M (-6.21%) | -1.77M (-30.86%) | -2.56M (-32.98%) | -3.82M (+187.22%) | -1.33M (+40.00%) | -950.00K (-2.06%) | -970.00K |
Other Income / Expenses | |||||||||||||
Interest Expense | 2.35M (+41.57%) | 1.66M (+22.96%) | 1.35M | - | - | 540K (+1250.00%) | 40K | - | - | 220K (+144.44%) | 90K | - | - |
Net Interest Income | - | 1.35M | -1.35M | - | - | 40K | -40.00K | - | - | - | - | - | - |
Other Non Operating Income | 2.85M | -18.28M (+1264.18%) | -1.34M (+509.09%) | -220.00K (+69.23%) | -130.00K (-65.79%) | -380.00K | 350K | -10.00K (-98.41%) | -630.00K (+21.15%) | -520.00K (+300.00%) | -130.00K (-27.78%) | -180.00K (+260.00%) | -50.00K |
Net Income | |||||||||||||
Income Before Tax | -10.24M (-64.18%) | -28.59M (+71.20%) | -16.70M (+384.06%) | -3.45M (+75.13%) | -1.97M (+2.07%) | -1.93M (+14.20%) | -1.69M (-4.52%) | -1.77M (-30.86%) | -2.56M | - | - | - | - |
Income Tax Expense | - | -6.92M (+1404.35%) | -460.00K | - | - | - | - | - | - | - | - | - | - |
Net Income From Continuing Operations | -10.24M (-52.72%) | -21.66M (+33.37%) | -16.24M (+370.72%) | -3.45M (+75.13%) | -1.97M (+2.07%) | -1.93M (+14.20%) | -1.69M (-4.52%) | -1.77M (-30.86%) | -2.56M (-36.63%) | -4.04M (+184.51%) | -1.42M (+49.47%) | -950.00K (-2.06%) | -970.00K |
Net Income | -10.24M (-52.72%) | -21.66M (+33.37%) | -16.24M (+370.72%) | -3.45M (+75.13%) | -1.97M (+2.07%) | -1.93M (+14.20%) | -1.69M (-4.52%) | -1.77M (-30.86%) | -2.56M (-36.63%) | -4.04M (+184.51%) | -1.42M (+49.47%) | -950.00K (-2.06%) | -970.00K |
Comprehensive Income Net Of Tax | -7.05M (-83.73%) | -43.32M | - | - | -1.97M (-75.22%) | -7.95M | - | - | - | - | - | - | - |